Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 7/20 | 0.46 |
| ▸ | THRA | P10827 | 5/20 | 0.45 |
| ▸ | BRD4 | O60885 | 6/20 | 0.43 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.43 |
| ▸ | BRD2 | P25440 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | RHEB | Q15382 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6795305 | 0.99 | THRB (0.47) | THRBTHRABRD4BRD3BRD2 | |
| SCHEMBL1642115 | 0.98 | THRB (0.47) | THRBTHRABRD4BRD3BRD2 | |
| SCHEMBL1640702 | 0.96 | THRB (0.47) | THRBTHRABRD4BRD3BRD2 | |
| SCHEMBL6270967 | 0.88 | THRB (0.51) | THRBTHRABRD4BRD3BRD2 | |
| SCHEMBL6268718 | 0.86 | THRB (0.46) | THRBTHRABRD4BRD3BRD2 | |
| SCHEMBL1641844 | 0.84 | THRB (0.53) | THRBTHRARHEB | |
| SCHEMBL6271002 | 0.84 | THRB (0.41) | THRBTHRABRD4BRD3BRD2 | |
| SCHEMBL1642414 | 0.83 | THRB (0.53) | THRBTHRARHEB | |
| SCHEMBL1641382 | 0.82 | THRB (0.55) | THRBTHRARHEB | |
| SCHEMBL1641445 | 0.82 | THRB (0.58) | THRBTHRABRD4BRD3BRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6723744-B2 | FOR THERAPY OF OBESITY, OVERWEIGHT CONDITION, HYPERLIPIDEMIA, GLAUCOMA, CARDIAC ARRHYTHMIAS, SKIN DISORDER, THYROID DISEASE, HYPOTHYROIDISM, THYROID CANCER, DIABETES, ATHEROSCLEROSIS, HYPERTENSION, CORONARY HEART DISEASE, HYPERCHOLESTEREMIA | PFIZER, INC. | 2004-04-20 | — | — | US | disclosed |
| US-20030078289-A1 | Indole carboxylic acids as thyroid receptor ligands | ASPNES GARY E (US) | 2003-04-24 | — | — | US | disclosed |
| EP-1297833-A1 | Indole carboxylic acids as thyroid receptor ligands | Pfizer Products Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078289-A1 | Indole carboxylic acids as thyroid receptor ligands | THRA, MC1R, THRB | THRB 3/4885THRA 1/4885BRD4 2998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.